Ono Pharmaceuticals and InveniAI Collaborate to Discover New Therapeutic Targets through Research Agreement
Monday, February 19, 2024
Ono Pharmaceutical Co., Ltd., based in Osaka, Japan, led by President and CEO Gyo Sagara, has announced a new research collaboration with InveniAI® LLC, headquartered in Guilford, Connecticut, USA, under the leadership of President and CEO Krishnan Nandabalan. This collaboration aims to utilize InveniAI's advanced artificial intelligence (AI) and machine learning (ML) technologies to identify innovative therapeutic targets.
According to the terms of the agreement, InveniAI will utilize its AI drug discovery platforms, including AlphaMeld® and ChatAlphaMeldTM, equipped with cutting-edge AI and ML algorithms and Generative AI tools, to identify novel therapeutic targets across various diseases specified by Ono. Subsequently, InveniAI will propose drug discovery hypotheses for optimization. Ono will then conduct validation studies to confirm the viability of these hypotheses for multiple therapeutic target candidates identified through InveniAI's drug discovery hypotheses. Ono will retain exclusive rights for the development and commercialization of resulting drug candidates worldwide.
Ono, expressed gratitude for InveniAI's technologies, emphasizing their ability to utilize vast amounts of data for innovative drug creation. Takino believes this collaboration will significantly enhance the efficiency of drug discovery research, ultimately leading to the provision of new therapeutic options globally.
InveniAI, LLC, expressed excitement about partnering with Ono, recognizing the company's dedication to innovation in drug discovery and development. He emphasized the collaborative effort's goal of expediting the identification of de-risked product opportunities. Nandabalan also highlighted InveniAI's commitment to integrating technological innovation into its processes to improve patient outcomes, mentioning recent advancements such as the incorporation of large language modules and generative AI, culminating in the creation of ChatAlphaMeld™—a transformative tool facilitating the seamless utilization of advanced technology across the organization.
Source: ono-pharma.com
